Testosterone Hormone Replacement Drug Class Prior Authorization Protocol
|
|
- Aron Ward
- 6 years ago
- Views:
Transcription
1 Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics Subcommittee. Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone undecanoate oil injectable), Fortesta (testosterone topical gel), Natesto (testosterone intranasal), Striant (testosterone buccal), Testim (testosterone topical gel), Testopel (testosterone pellets), Depo-Testosterone (testosterone cypionate injectable), Testosterone enanthate (testosterone injectable), Testosterone transdermal gel, Vogelxo (testosterone topical) FDA Approved Indications: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone undecanoate oil injectable), Fortesta (testosterone topical gel), Natesto (testosterone intranasal), Striant (testosterone buccal), Testim (testosterone topical gel), Testopel (testosterone pellets), Depo-Testosterone (testosterone cypionate injectable), Testosterone enanthate, Vogelxo (testosterone topical) Replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone Treatment of advancing, metastatic (skeletal) mammary cancer in postmenopausal females Treatment of breast cancer in premenopausal females Testosterone enanthate
2 Policy/Criteria: A. Testosterone Cypionate a. Restricted to the treatment of primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). Specialist: No restriction Criteria: Confirmed diagnosis. Formulary Status: Formulary, Code 1 B. Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone undecanoate oil injectable), Fortesta (testosterone topical gel), Natesto (testosterone intranasal), Striant (testosterone buccal), Testim (testosterone topical gel), Testopel (testosterone pellets), Testosterone enanthate, Vogelxo (testosterone topical) a. Treatment of hypogonadism; OR b. Treatment of HIV-associated male hypogonadism; OR c. Treatment of HIV-associated wasting syndrome Specialist: HIV or infectious disease specialist (HIV-associated hypogonadism or wasting syndrome only) Criteria: a. Treatment of hypogonadism: i. Male; ii. Documented pretreatment serum testosterone levels less than the laboratory s lower reference limit; iii. Failure or clinically significant adverse effects to one of the preferred alternatives: Androderm, testosterone 1% transdermal gel, testosterone cypionate or testosterone enanthate. b. Treatment of HIV-associated male hypogonadism: i. Documented pretreatment total testosterone levels less than the median ageadjusted testosterone levels or less than the laboratory s lower reference limit; ii. Failure or clinically significant adverse effects to one of the preferred alternatives: Androderm, testosterone 1% transdermal gel, testosterone cypionate or testosterone enanthate. c. Treatment of HIV-associated wasting syndrome: i. Confirmed symptoms of muscle and/or weight loss (e.g. 10% or greater weight loss from baseline, or less than 90% ideal body weight);
3 ii. Failure or clinically significant adverse effects to one of the preferred alternatives: Androderm, testosterone 1% transdermal gel, testosterone cypionate or testosterone enanthate. Re-authorization Criteria: a. Treatment of hypogonadism: i. Serum testosterone level within or below normal limits of the reporting lab; OR ii. Serum testosterone level outside of upper limits of normal for the reporting lab AND the dose is adjusted b. Treatment of HIV-associated male hypogonadism OR HIV-associated wasting syndrome: i. Documentation of meeting therapeutic goal (e.g. improvement in weight, lean body mass, testosterone level, energy, depression, etc.) Authorization Duration: 6 months Formulary Status: a. Androderm, testosterone 1% transdermal gel, testosterone enanthate: Nonformulary preferred; PA applies b. Others: Non-formulary; PA applies C. Testosterone enanthate a. Treatment of advancing, metastatic (skeletal) mammary cancer in postmenopausal females; OR b. Treatment of breast cancer in premenopausal females; Specialist: Oncologist Criteria: a. Confirmed diagnosis OR primary NCCN guideline approved regimen Authorization Duration: 12 months Formulary Status: Non-formulary preferred; PA applies
4 D. Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone undecanoate oil injectable), Fortesta (testosterone topical gel), Natesto (testosterone intranasal), Striant (testosterone buccal), Testim (testosterone topical gel), Testopel (testosterone pellets), Testosterone enanthate, Vogelxo (testosterone topical) a. Transgender hormonal treatment Criteria: a. Please refer to Transgender Hormonal Treatment Policy Authorization Duration: 12 months Clinical Justification: 2010 The Endocrine Society s Clinical Guidelines: Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes Recommend that clinicians measure morning total serum testosterone level by a reliable assay in patients with clinical manifestations or less specific symptoms and signs, as the initial diagnostic test. Recommend confirmation of the diagnosis by repeating measurement of total testosterone. Recommend measurement of free or bioavailable testosterone level, using an accurate and reliable assay, in some men in whom total testosterone concentrations are near the lower limit of the normal range and in whom alterations of SHBG are suspected. Recommend testosterone therapy for symptomatic men with confirmed classical androgen deficiency syndromes aimed at inducing and maintaining secondary sex characteristics and at improving their sexual function, sense of well-being and bone mineral density. Recommend that clinicians consider short-term testosterone therapy as an adjunctive therapy in HIV-infected men with low testosterone levels and weight loss to promote weight maintenance and gains in lean body mass and muscle strength. The therapeutic target should be to raise serum testosterone levels into a range that is mid-normal for healthy, young men. Summary Hypogonadism in men is a clinical syndrome that results from failure of the testes to produce physiological levels of testosterone or a normal number of spermatozoa due to disruption of the hypothalamic-pituitary-testicular axis. Symptoms include reduced sexual desire and activity, fatigue, depression, lack of concentration, and sleep disturbances. Most T measurements in typical clinical laboratories may be >30% different from true serum T concentrations due to differences in assays and technique. The Endocrine Society recommends that clinicians use the lower reference limit for healthy young men
5 established for the laboratory assay as the cut-off for hypogonadism. The American Urology Association suggests that when the results of the total testosterone are equivocal ( ng/dl), it would be wise to confirm results with a second test measuring free testosterone levels. The target total testosterone range for young adult males on replacement therapy is ng/dl. Most clinical studies on testosterone replacement were conducted in young males. Given that multiple comorbidities can lower total testosterone, such as age and obesity, some have suggested using age-adjusted testosterone levels to establish cut-offs and target levels for hypogonadism. However, no studies have validated using ageadjusted testosterone levels. The Endocrine Society suggests using a lower target range of ng/dl in older adult males. The risks of testosterone replacement include the possibility of cardiovascular events, prostate growth, sleep apnea, urinary retention, and decreased HDL. It is not recommended to initiate therapy in patients with breast or prostate cancer. There is a high prevalence of low testosterone levels in HIV-infected men. Low testosterone levels in these patients result in weight and muscle loss, progression to AIDS, and depression. The Infectious Diseases Society of America recommends obtaining morning testosterone levels in patients exhibiting fatigue, weight loss, or evidence of reduced bone mineral density and initiating short-term testosterone replacement once a diagnosis of hypogonadism is established. Obtaining free testosterone levels in this population may be useful to confirm diagnosis as many patients will have false normal testosterone levels due to elevated SHBG. Testosterone replacement is not recommended by the Infectious Diseases Society of America in eugonadal patients who present with HIV wasting syndrome. However, in one meta-analysis review of testosterone in HIV wasting syndrome, two small clinical studies that were included involved patients who were eugonadal at baseline. The conclusion of the meta-analysis was that testosterone was helpful for lean body mass recovery in patients with low to low-normal testosterone levels; however, safety with long-term testosterone administration remains unclear. According to the Endocrine Society s Clinical Practice Guideline, Androgen Therapy in Women, although there is evidence for short-term efficacy of testosterone in selected populations such as surgically menopausal women, the generalized use of testosterone by women is not recommended, due to inadequate indication and evidence of safety in longterm studies. References: 1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endo Metab 2010;95(6): Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endo Metab 2006;91(6): Paduch DA, Brannigan RE, Fuchs EF, et al. The laboratory diagnosis of testosterone deficiency. Amer Uro Assoc Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with HIV: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009;49: Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002;2:
6 6. Rabkin, JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psych 2000;57: Bassil N, Alkaade Saad, Morley JE. The benefits and risk of testosterone replacement therapy: a review. Ther Clin Risk Mgmt 2009;5: Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. NEJM 2010;363(2): Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endo Metab 2004;89(8): Rabkin JG, Wagner GJ, Rakin R. Testosterone therapy for HIV positive men with and without hypogonadism. J Clin Psychpharm 1999;19(1): Fairfield WP, Finkelstein JS, Klibanski A, et al. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endo Metab 2001;86: Declining Androgens with Age: An Overview. Available at: Accessed November 4, Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women, an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014;99(10):3489. Change Control Date Change 08/16/2017 Added Re-authorization criteria to include: a. Treatment of HIV-associated male hypogonadism OR HIVassociated wasting syndrome: ii. Documentation of meeting therapeutic goal (e.g. improvement in weight, lean body mass, testosterone level, energy, depression, etc.)
Drug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationTestosterone Topical/Buccal/Nasal
BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES TESTOSTERON. Generic Brand HICL GCN Exception/Other ROUTE MISCELL.
Generic Brand HICL GCN Exception/Other ANDRODERM 01403 ROUTE MISCELL. ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO DEPO- 01400 ROUTE MISCELL. CYPIONATE TESTOSTERON E GCN 38586 DELATESTRYL 01401
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationMedication Policy Manual
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Non-preferred, non-transdermal testosterone replacement therapy products (Android, Aveed, Androxy, Methitest,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 57 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Androgens and Anabolic Steroids Page 1 of 53 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Androgens and Anabolic Steroids Prime Therapeutics will review Prior
More informationPolicy. covered: bilateral. alcohol or. Approve. 3. Palliative enanthate injection in. women for. 6 months if. can also sponsive tumor.
Injectablee Testosterone Products Prior Authorization Policy Number: 5.01.597 Origination: 07/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for injectable testosterone
More informationClinical Policy: Testosterone Reference Number: AZ.CP.PHAR.02 Effective Date: Last Review Date: Line of Business: Arizona Medicaid
Clinical Policy: Reference Number: AZ.CP.PHAR.02 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for
More informationSeptember 17, FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT):
JOINT MEETING FOR BONE, REPRODUCTIVE AND UROLOGIC DRUGS ADVISORY COMMITTEE (BRUDAC) AND THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE (DSARM AC) September 17, 2014 FDA background documents for
More informationMI Androgen Deficiency Hypogonadism
MI Androgen Deficiency Hypogonadism WADA TUE Expert Group John A Lombardo, MD October 2014, Columbus, Ohio USA Hypothalamic-Pituitary-Gonadal Axis / 2 Hypogonadism/Androgen Deficiency Clinical syndrome:
More informationInsight into male menopause'
Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone
More informationJeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017
Jeremiah Murphy, MD Mercy Urology Clinic October 21, 2017 Describe an appropriate strategy for the evaluation and diagnosis of male hypogonadism Endocrine Society Clinical Practice Guideline-2010 Review
More informationMedical Policy Testosterone Therapy
Medical Policy Testosterone Therapy Subject: Testosterone Therapy Effective Date: April 2015 Overview: Testosterone cypionate, testosterone enanthate, testosterone undecanoate, and testosterone pellet
More informationMonth/Year of Review: September 2013 Date of Last Review: December 2009
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2013 Oregon State University. All Rights
More informationInappropriate Testosterone Billings
Inappropriate Testosterone Billings Carla Patrick-Fagan March 30, 2015 Truven Health Analytics Inc. All Rights Reserved. 1 Agenda Proposed in the 2015 analytic plan Steroid prescriptions Code of Federal
More informationThe Testosterone Quandary. Beth Crowder, PhD, APRN
The Testosterone Quandary Beth Crowder, PhD, APRN Objectives Define testosterone, the hypothalamic-pituitary-gonadotrophic axis, and normal blood levels List functions of testosterone and symptoms of low
More informationThe ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate
The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women s logo is placed throughout
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Current and Novel Therapeutic Options Module 4 2 Objectives Identify desirable characteristics of ideal testosterone formulations Review
More informationOriginal Research Declining testicular function in aging men
(2003) 15, Suppl 4, S3 S8 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Original Research 1 * 1 Wesley Woods Health Center, Atlanta, Georgia, USA Age-related
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationChapter 5. General discussion
Chapter 5. General discussion 127 Chapter 5 In 2003, two review papers concluded that endogenous androgens do not show any consistent association with cardiovascular disease (CVD) risk 1,2. Apparently,
More informationAll About T Testosterone for FTMs. Presented by John Otto, MLIS
All About T Testosterone for FTMs Presented by John Otto, MLIS Who? Anyone thinking about transitioning Those who have transitioned, but want to know more Empowerment from self-managing transition Allies
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred Topical Androgen Criteria Program Summary
OBJECTIVE The intent of the Androgens and Anabolic Steroids Prior Authorization with Quantity Limit (PA) program is to appropriately select patients for therapy according to product labeling and/or clinical
More informationAffirming Care of the Transgender Patient
Mountain West AIDS Education and Training Center Affirming Care of the Transgender Patient Jessica Rongitsch, MD, FACP This presentation is intended for educational use only, and does not in any way constitute
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationAndrogens and Anabolic Steroids Prior Authorization and Quantity Limit Program Summary
Androgens and Anabolic Steroids Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-11,27,28,32,33,37-39,41,42,46,50 Topical Androgen Agents Agent Indication Dosage
More informationFemale testosterone level chart
Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9
More informationTestosterone Replacement Therapy
30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca Testosterone Replacement Therapy Environmental Scan and Local/Historical Context December 1, 2014 2 Executive Summary Part A: Pharmacy Benefit
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More informationTreatment of androgen deficiency in the aging male
Treatment of androgen deficiency in the aging male The Practice Committee of the American Society for Reproductive Medicine Birmingham, Alabama Although guidelines for androgen replacement therapy for
More informationMonitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc.
Mr Mark Newman Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc. 2 Avoiding Pitfalls in (B)HRT Monitoring and Picking the Right Lab Test Objectives: Outline how expected
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Implantable Hormone Pellets Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 6 Effective Date...
More informationSUMMARY and OBJECTIVES. LOW T- I m half the man I used to be. Prevalence of Low-T. Definition of Hypogonadism 9/19/ Million men in the US
SUMMARY and OBJECTIVES LOW T- I m half the man I used to be A discussion of male hypogonadism David Doriguzzi, PA-C Valley Endocrine & Diabetes Consultants Definition Prevalence Causes Signs & Symptoms
More informationTransgender 201: Case Discussion Group
Transgender 201: Case Discussion Group Melissa Davis, MD Maria Barnett, DO October 19, 2017 Maria Barnett, DO, Date Welcome! Disclosures Introductions Discussion The total time of this workshop will depend
More informationTestosterone Use and Effects
Parkland College Natural Sciences Poster Sessions Student Works 2013 Testosterone Use and Effects Brandon Mills Parkland College Recommended Citation Mills, Brandon, "Testosterone Use and Effects" (2013).
More informationComparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism
Brigham Young University BYU ScholarsArchive All Student Publications 2016-07-27 Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism Christopher M. Williams Brigham
More informationArthi Thirumalai 1, Kathryn E. Berkseth 1, John K. Amory 2
REVIEW Treatment of Hypogonadism: Current and Future Therapies [version 1; referees: 2 approved] Arthi Thirumalai 1, Kathryn E. Berkseth 1, John K. Amory 2 1Division of Metabolism, Endocrinology, and Nutrition,
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (LPCN - NASDAQ) INITIATION ZACKS ESTIMATES
Small-Cap Research August 18, 2014 Jason Napodano, CFA David Bautz, PhD 312-265-9421 / jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Lipocine, Inc. (LPCN - NASDAQ)
More informationIcd-10 low levels of testosterone
Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases
More informationIcd 10 hormone replacement therapy male
Icd 10 hormone replacement therapy male 2018 ICD - 10 code for Hormone replacement therapy is Z79.890. Lookup the complete ICD 10 Code details for Z79.890. The ICD - 10 system requires that. TEENren who
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s International Pharmacy staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women
More informationAssociate Professor Geoff Braatvedt
Associate Professor Geoff Braatvedt Endocrinologist Diabetologist and Physician Green Lane and Auckland City Hospitals Auckland 14:00-14:55 WS #145: Approach to Low Testosterone Values 15:05-16:00 WS #157:
More informationThe physiology of normal androgen production in
Mayo Clin Proc, April 2004, Vol 79 (Supplement) Formulations and Use of Androgens S3 Supplement Article Formulations and Use of Androgens in Women MICHELINE C. CHU, MD, AND ROGERIO A. LOBO, MD The physiology
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More information1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride
1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride
More informationTestosterone as a Therapeutic Tool
330 Medicine Update 56 Testosterone as a Therapeutic Tool SV MADHU INTRODUCTION Testosterone preparations have been available for many years and have been used by physicians primarily to treat sexual problems.
More informationTREATMENT OPTIONS FOR MALE HYPOGONADISM
TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,
More informationMale Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2
Male Hormone Replacement Therapy Punita Dhindsa D.O PGY 2 Physiology of Testosterone & Causes of Hypogonadism in Males The use of testosterone therapy is very common in the US, with an estimated 2.3 million
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More informationFINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM
750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride
More informationCpt code for testosterone cypionate injection
Cpt code for testosterone cypionate injection As the number of people taking injections. Number: 0007. Policy. Aetna considers the diagnosis and treatment of erectile dysfunction (impotence) medically
More informationAlthough women produce only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Mary Lake Polan, MD, PhD, MPH Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Chair Emeritus,
More informationAndrogen deficiency in the aging male
Androgen deficiency in the aging male Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology The American Society for Reproductive
More informationUpdates on Anti-doping and TUE Management in Paralympic Sport
International Paralympic Committee Updates on Anti-doping and TUE Management in Paralympic Sport Matthew Fedoruk, Ph.D. March 15, 2018 PyeongChang 2018 IPC Medical / Sports Science Committee Workshops
More informationXYOSTED (testosterone enanthate) injection, for subcutaneous use CIII Initial US approval: 1953 IMPORTANT SAFETY INFORMATION
ANTARES PHARMA ANNOUNCES THE COMMERCIAL AVAILABILITY OF XYOSTED (TESTOSTERONE ENANTHATE) INJECTION A NEW TREATMENT FOR ADULT MEN DIAGNOSED WITH TESTOSTERONE DEFICIENCY XYOSTED - A Novel Subcutaneous Testosterone
More informationGrowth Hormone & Somatotropin are an Ergogenic Aid
Growth Hormone & Somatotropin are an Ergogenic Aid BPK 312 MARCH 28 2017 MICHAEL MORKOS PAUL SOURIAL DEL INGVALDSON Table of Contents 1. Hypothesis 2. Clinical Use 3. Mechanism of Action 4. Growth hormone
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNew long-acting androgens
World J Urol (2003) 21: 306 310 DOI 10.1007/s00345-003-0364-x TOPIC PAPER Louis J. Gooren New long-acting androgens Received: 16 September 2003 / Accepted: 17 September 2003 / Published online: 9 October
More informationHypogonadism and Testosterone Replacement Therapy
Testosterone Replacement Therapy Hypogonadism and Testosterone Replacement Therapy a report by Adrian S Dobs, MD, MHS and Anjana Myneni, MD Professor of Medicine and Oncology, Department of Medicine, Johns
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Human, Recombinant) Reference Number: CP.CPA.76 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationCase ILN/1:14-cv Document 1 Filed 04/30/14 Page 1 of 10 BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION ) ) ) ) ) )
Case ILN/1:14-cv-02934 Document 1 Filed 04/30/14 Page 1 of 10 BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: ANDROGEL PRODUCTS LIABILITY LITIGATION MDL DOCKET NO. 2545 OPPOSITION OF DEFENDANTS
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic
More informationRobert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration
-------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the
More informationCreatine Versus Anabolic Steroids. Over the past few years, many athletes have been using performance-enhancing
Hester 1 Kyle Hester Instructor s Name ENGL 1013 Date Creatine Versus Anabolic Steroids Over the past few years, many athletes have been using performance-enhancing supplements on a regular basis. Two
More informationOF THE one thousand generations of humans that have
0021-972X/98/$03.00/0 Vol. 83, No. 10 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society THERAPEUTIC PERSPECTIVE Issues in Testosterone Replacement
More informationHAIR LOSS HORMONE IMBALANCE HAIR LOSS HORMONE IMBALANCE PDF HAIR LOSS - WIKIPEDIA HORMONE IMBALANCE CHECKLIST - WEIGHT LOSS PROGRAMS
PDF HAIR LOSS - WIKIPEDIA HORMONE IMBALANCE CHECKLIST - WEIGHT LOSS PROGRAMS 1 / 6 2 / 6 3 / 6 hair loss hormone imbalance pdf Male pattern hair loss is believed to be due to a combination of genetics
More informationRisks and benefits of testosterone therapy in older men. Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison and Shalender Bhasin
Risks and benefits of testosterone therapy in older men Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison and Shalender Bhasin Abstract In young men (defined as age
More informationMale hypogonadism is a clinical syndrome that
Journal of Andrology, Vol. 33, No. 4, July/August 2012 Copyright E American Society of Andrology A Novel Testosterone 2% Gel for the Treatment of Hypogonadal Males ADRIAN S. DOBS,* JOHN MCGETTIGAN,{ PAUL
More informationTESTIM (testosterone gel) for topical use, CIII Initial U.S. Approval: 1953
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TESTIM safely and effectively. See full prescribing information for TESTIM. TESTIM (testosterone
More informationTESTOVIRON 300 TESTOCYP 200 INJECTABLE PRODUCTS
Platinum Biotech has a commitment to all people, a commitment of improving the quality of life for each and every person worldwide, through which we constantly strive to innovate, improve and increase
More informationLong-term experience with testosterone replacement through scrotal skin
CHAPTER 13 1 Long-term experience with testosterone replacement through scrotal skin Linda E. Atkinson, Yu-Lin Chang, and Peter J. Snyder Contents 13.1 13.1.1 13.1.2 13.2 13.2.1 13.2.2 13.2.2.1 13.2.2.2
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationPRODUCT INFORMATION PROVIRON
PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5
More informationCinryze. Cinryze (C1 esterase inhibitor [human]) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.05 Subject: Cinryze Page: 1 of 5 Last Review Date: September 20, 2018 Cinryze Description Cinryze
More informationAre Steroids Worth the Risk?
Are Steroids Worth the Risk? Dominic has baseball on the brain. Just being good isn't enough he wants to be the best. He dreams of playing in the majors someday, but worries about the intense competition
More informationScreening and Monitoring in Men Prescribed Testosterone Therapy in the U.S.,
Research Articles Screening and Monitoring in Men Prescribed Testosterone Therapy in the U.S., 2001 2010 Jacques Baillargeon, PhD a,b Randall J. Urban, MD b,c Yong-Fang Kuo, PhD a,b,c Holly M. Holmes,
More informationPros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery
Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery David T Zava, PhD ZRT laboratory A Guide to Steroid Hormone Testing in Different Body Fluids Following
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218
More informationMens Health Post Puberty. Nayan Patel PharmD
Mens Health Post Puberty Nayan Patel PharmD Definition of Androgen Deficiency * Consistently low testosterone * Associated signs/symptoms * Evidence based review of literature * Data is weak at best Definition
More informationUse of Performance Enhancing Substances Good Chemistry Gone Bad. Evan M. Klass, M.D., F.A.C.P.
Use of Performance Enhancing Substances 2017 Good Chemistry Gone Bad Evan M. Klass, M.D., F.A.C.P. Doping the use of banned athletic performance-enhancing drugs by competitors Performance enhancing substances
More informationPackage Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)
Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains
More informationCONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS
CONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS 13 Septembre 2018 Quebec, Canada 1 ENDOCEUTICS No. 1 Innovative pharmaceutical company in menopausal women s health in the world 2 Facilities Head
More informationPHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor
PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme
More informationpump. a metered-dose pump that delivers 30 mg of testosterone per twist. Each metered-dose pump is supplied with an applicator.
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AXIRON safely and effectively. See full prescribing information for AXIRON. AXIRON (testosterone)
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationANDROGENS PLAY AN essential role in the sexual
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5429 5434 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0897 Intramuscular Testosterone
More informationDr Tarza Jamal Pharmacology Lecture 2
Contraceptives and androgen hormone Contraceptives: Currently, interference with ovulation is the most common pharmacologic intervention for preventing pregnancy. Major classes of contraceptives 1. Combination
More informationGrowth Hormone s Impact as a Safe Ergogenic Aid to Increase Body Size
Growth Hormone s Impact as a Safe Ergogenic Aid to Increase Body Size Point Argument: Growth Hormone is a Safe Ergogenic Aid to Increase Body Size Monica Chauhan Carissa Eastwood Emily Lefler Mar. 28,
More information